Grouped by gene, many of these novel mutations comprised large gains in absolute counts and in percent increase (Figure 6A and B), including MAP3K1 and GATA3 in breast cancer, and NOTCH2 and CDKN2A in lung cancer. This evidence concerns the gene MAP3K1 and lung carcinoma.